Views on Lupin launches Duloxetine 40mg Delayed-Release Capsules (Generic Cymbalta): Angel Broking

Views of Ms. Sarabjit Kour Nangra (VP Research - Pharma, Angel Broking)

Lupin launches Duloxetine 40mg Delayed-Release Capsules (Generic Cymbalta®):

"Lupin announced that its subsidiary Lupin Pharmaceuticals Inc. (Lupin) has launched its Duloxetine 40mg Delayed-Release (DR) Capsule, which is the first and only generic Duloxetine formulation to be made available in 40mg dosage strength. Lupin is the only generic manufacturer to offer all Duloxetine dosage strengths - the 20 mg, 30mg, 60 mg, and now the newest 40mg.

Lupin's generic Duloxetine 40mg DR capsules are therefore the first and only capsule available for patients in this dosage strength. Cymbalta® Delayed-Release Capsules 20mg, 30mg and 60mg strengths had annual U.S sales of approximately US$1.05bn (Brand + Generics - IMS MAT June 2015). Given the high competition (almost 12-13 players) for the product, we believe that the product will not significantly contribute to the overall sales & profitability of the company. We remain NEUTRAL on the stock."

Shares of LUPIN LTD. was last trading in BSE at Rs.1869.8 as compared to the previous close of Rs. 1880.7. The total number of shares traded during the day was 53142 in over 3358 trades.

The stock hit an intraday high of Rs. 1895.25 and intraday low of 1851.1. The net turnover during the day was Rs. 99217574.

Source : Equity Bulls

Keywords